Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Haggstrom, S; Stattin, P; Wikstrom, P; Bergh, A; Damber, JE
   Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer
   BJU INTERNATIONAL
   
   S. Haggstrom et al., "Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer", BJU INT, 88(1), 2001, pp. 110-116
2. Lukanova, A; Toniolo, P; Akhmedkhanov, A; Hunt, K; Rinaldi, S; Zeleniuch-Jacquotte, A; Haley, NJ; Riboli, E; Stattin, P; Lundin, E; Kaaks, R
   A cross-sectional study of IGF-1 determinants in women
   EUROPEAN JOURNAL OF CANCER PREVENTION
   
   A. Lukanova et al., "A cross-sectional study of IGF-1 determinants in women", EUR J CAN P, 10(5), 2001, pp. 443-452
3. Tieva, A; Stattin, P; Wikstrom, P; Bergh, A; Damber, JE
   Gonadotropin-releasing hormone receptor expression in the human prostate
   PROSTATE
   
   A. Tieva et al., "Gonadotropin-releasing hormone receptor expression in the human prostate", PROSTATE, 47(4), 2001, pp. 276-284
4. Stattin, P; Stenman, UH; Riboli, E; Hallmans, G; Kaaks, R
   Prostate cancer screening
   LANCET
   
   P. Stattin et al., "Prostate cancer screening", LANCET, 357(9263), 2001, pp. 1202-1203
5. Stattin, P; Kaaks, R; Riboli, E; Ferrari, P; Dechaud, H; Hallmans, G
   Circulating insulin-like growth factor-I and benign prostatic hyperplasia - A prospective study
   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
   
   P. Stattin et al., "Circulating insulin-like growth factor-I and benign prostatic hyperplasia - A prospective study", SC J UROL N, 35(2), 2001, pp. 122-126
6. Ljungberg, B; Bozoky, B; Kovacs, G; Stattin, P; Farrelly, E; Nylander, K; Landberg, G
   p53 expression in correlation to clinical outcome in patients with renal cell carcinoma
   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
   
   B. Ljungberg et al., "p53 expression in correlation to clinical outcome in patients with renal cell carcinoma", SC J UROL N, 35(1), 2001, pp. 15-20
7. Stattin, P; Soderberg, S; Hallmans, G; Bylund, A; Kaaks, R; Stenman, UH; Bergh, A; Olsson, T
   Leptin is associated with increased prostate cancer risk: A nested case-referent study
   JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
   
   P. Stattin et al., "Leptin is associated with increased prostate cancer risk: A nested case-referent study", J CLIN END, 86(3), 2001, pp. 1341-1345
8. Stattin, P; Rinaldi, S; Stenman, UH; Riboli, E; Hallmans, G; Bergh, A; Kaaks, R
   Plasma prolactin and prostate cancer risk: A prospective study
   INTERNATIONAL JOURNAL OF CANCER
   
   P. Stattin et al., "Plasma prolactin and prostate cancer risk: A prospective study", INT J CANC, 92(3), 2001, pp. 463-465
9. Kaaks, R; Soderberg, S; Olsson, T; Hallmans, G; Stattin, P
   Re: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study - Response
   JOURNAL OF THE NATIONAL CANCER INSTITUTE
   
   R. Kaaks et al., "Re: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study - Response", J NAT CANC, 93(8), 2001, pp. 650-651
10. Lissbrant, IF; Stattin, P; Wikstrom, P; Damber, JE; Egevad, L; Bergh, A
    Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival
    INTERNATIONAL JOURNAL OF ONCOLOGY
    
    I.F. Lissbrant et al., "Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival", INT J ONCOL, 17(3), 2000, pp. 445-451
11. Wikstrom, P; Wikstrom, P; Lissbrant, IF; Bergh, A; Damber, JE; Stattin, P
    Evaluation of prognostic factors in prostate cancer with partial least squares analysis
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
    
    P. Wikstrom et al., "Evaluation of prognostic factors in prostate cancer with partial least squares analysis", SC J UROL N, 34(4), 2000, pp. 252-256
12. Stattin, P; Bylund, A; Rinaldi, S; Biessy, C; Dechaud, H; Stenman, UH; Egevad, L; Riboli, E; Hallmans, G; Kaaks, R
    Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study
    JOURNAL OF THE NATIONAL CANCER INSTITUTE
    
    P. Stattin et al., "Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study", J NAT CANC, 92(23), 2000, pp. 1910-1917
13. Wikstrom, P; Westin, P; Stattin, P; Damber, JE; Bergh, A
    Early castration-induced upregulation of transforming growth factor beta 1and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients
    PROSTATE
    
    P. Wikstrom et al., "Early castration-induced upregulation of transforming growth factor beta 1and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients", PROSTATE, 38(4), 1999, pp. 268-277
14. WIKSTROM P; STATTIN P; FRANCKLISSBRANT I; DAMBER JE; BERGH A
    TRANSFORMING-GROWTH-FACTOR BETA-1 IS ASSOCIATED WITH ANGIOGENESIS, METASTASIS, AND POOR CLINICAL OUTCOME IN PROSTATE-CANCER
    The Prostate
    
    P. Wikstrom et al., "TRANSFORMING-GROWTH-FACTOR BETA-1 IS ASSOCIATED WITH ANGIOGENESIS, METASTASIS, AND POOR CLINICAL OUTCOME IN PROSTATE-CANCER", The Prostate, 37(1), 1998, pp. 19-29
15. Bylund, A; Stattin, P; Widmark, A; Bergh, A
    Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy
    RADIOTHERAPY AND ONCOLOGY
    
    A. Bylund et al., "Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy", RADIOTH ONC, 49(2), 1998, pp. 143-148
16. STATTIN P; WESTIN P; DAMBER JE; BERGH A
    SHORT-TERM CELLULAR EFFECTS INDUCED BY CASTRATION THERAPY IN RELATIONTO CLINICAL OUTCOME IN PROSTATE-CANCER
    British Journal of Cancer
    
    P. Stattin et al., "SHORT-TERM CELLULAR EFFECTS INDUCED BY CASTRATION THERAPY IN RELATIONTO CLINICAL OUTCOME IN PROSTATE-CANCER", British Journal of Cancer, 77(4), 1998, pp. 670-675
17. STATTIN P; BERGH A; KARLBERG L; TAVELIN B; DAMBER JE
    LONG-TERM OUTCOME OF CONSERVATIVE THERAPY IN MEN PRESENTING WITH VOIDING SYMPTOMS AND PROSTATE-CANCER
    European urology
    
    P. Stattin et al., "LONG-TERM OUTCOME OF CONSERVATIVE THERAPY IN MEN PRESENTING WITH VOIDING SYMPTOMS AND PROSTATE-CANCER", European urology, 32(4), 1997, pp. 404-409
18. LISSBRANT IF; STATTIN P; DAMBER JE; BERGH A
    VASCULAR DENSITY IS A PREDICTOR OF CANCER-SPECIFIC SURVIVAL IN PROSTATIC-CARCINOMA
    The Prostate
    
    I.F. Lissbrant et al., "VASCULAR DENSITY IS A PREDICTOR OF CANCER-SPECIFIC SURVIVAL IN PROSTATIC-CARCINOMA", The Prostate, 33(1), 1997, pp. 38-45
19. STATTIN P
    PROGNOSTIC FACTORS IN PROSTATE-CANCER
    Scandinavian journal of urology and nephrology
    
    P. Stattin, "PROGNOSTIC FACTORS IN PROSTATE-CANCER", Scandinavian journal of urology and nephrology, 31, 1997, pp. 4-46
20. STATTIN P; DAMBER JE; KARLBERG L; BERGH A
    CELL-PROLIFERATION ASSESSED BY KI-67 IMMUNOREACTIVITY ON FORMALIN-FIXED TISSUES IS A PREDICTIVE FACTOR FOR SURVIVAL IN PROSTATE-CANCER
    The Journal of urology
    
    P. Stattin et al., "CELL-PROLIFERATION ASSESSED BY KI-67 IMMUNOREACTIVITY ON FORMALIN-FIXED TISSUES IS A PREDICTIVE FACTOR FOR SURVIVAL IN PROSTATE-CANCER", The Journal of urology, 157(1), 1997, pp. 219-222
21. STATTIN P; DAMBER JE; MODIG H; BERGH A
    PRETREATMENT P53 IMMUNOREACTIVITY DOES NOT INFER RADIORESISTANCE IN PROSTATE-CANCER PATIENTS
    International journal of radiation oncology, biology, physics
    
    P. Stattin et al., "PRETREATMENT P53 IMMUNOREACTIVITY DOES NOT INFER RADIORESISTANCE IN PROSTATE-CANCER PATIENTS", International journal of radiation oncology, biology, physics, 35(5), 1996, pp. 885-889
22. STATTIN P; BERGH A; KARLBERG L; NORDGREN H; DAMBER JE
    P53 IMMUNOREACTIVITY AS PROGNOSTIC MARKET FOR CANCER-SPECIFIC SURVIVAL IN PROSTATE-CANCER
    European urology
    
    P. Stattin et al., "P53 IMMUNOREACTIVITY AS PROGNOSTIC MARKET FOR CANCER-SPECIFIC SURVIVAL IN PROSTATE-CANCER", European urology, 30(1), 1996, pp. 65-72
23. STATTIN P; DAMBER JE; KARLBERG L; NORDGREN H; BERGH A
    BCL-2 IMMUNOREACTIVITY IN PROSTATE TUMORIGENESIS IN RELATION TO PROSTATIC INTRAEPITHELIAL NEOPLASIA, GRADE, HORMONAL STATUS, METASTATIC GROWTH AND SURVIVAL
    Urological research
    
    P. Stattin et al., "BCL-2 IMMUNOREACTIVITY IN PROSTATE TUMORIGENESIS IN RELATION TO PROSTATIC INTRAEPITHELIAL NEOPLASIA, GRADE, HORMONAL STATUS, METASTATIC GROWTH AND SURVIVAL", Urological research, 24(5), 1996, pp. 257-264
24. STATTIN P; KARLBERG L; DAMBER JE
    LONG-TERM OUTCOME OF PATIENTS TREATED FOR HYDROCELE WITH THE SCLEROSANT AGENT SODIUM TETRADECYL SULFATE
    Scandinavian journal of urology and nephrology
    
    P. Stattin et al., "LONG-TERM OUTCOME OF PATIENTS TREATED FOR HYDROCELE WITH THE SCLEROSANT AGENT SODIUM TETRADECYL SULFATE", Scandinavian journal of urology and nephrology, 30(2), 1996, pp. 109-113
25. WESTIN P; STATTIN P; DAMBER JE; BERGH A
    CASTRATION THERAPY RAPIDLY INDUCES APOPTOSIS IN A MINORITY AND DECREASES CELL-PROLIFERATION IN A MAJORITY OF HUMAN PROSTATIC TUMORS
    The American journal of pathology
    
    P. Westin et al., "CASTRATION THERAPY RAPIDLY INDUCES APOPTOSIS IN A MINORITY AND DECREASES CELL-PROLIFERATION IN A MAJORITY OF HUMAN PROSTATIC TUMORS", The American journal of pathology, 146(6), 1995, pp. 1368-1375